Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors

Eryk Latoch1 · Katarzyna Konończuk1 · Katarzyna Taranta-Janusz2 · Katarzyna Muszyńska-Rosłan1 · Edyta Szymczak2 · Anna Wasilewska2 · Maryna Krawczuk-Rybak1

Received: 15 May 2020 / Accepted: 3 October 2020 / Published online: 14 October 2020 © The Author(s) 2020

Abstract

Introduction Nephrotoxicity is a potential adverse effect of anticancer treatment in childhood. Cytostatics, abdominal radiotherapy, total body irradiation (TBI) and some agents used in supportive care may induce acute kidney injury (AKI) or lead to chronic kidney disease (CKD). The aim of this study was to test the hypothesis whether urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are increased in acute lymphoblastic leukemia (ALL) survivors.

Method The study cohort consisted of 86 patients (42 females) previously treated for ALL. The median time after cessation of treatment was 6.55 (IQR: 1.96–9.93) years and median age at the time of study: 12 (IQR: 6.76–16.00). The control group included 53 healthy peers. Immunoenzymatic ELISA commercial kits were used to measure urine KIM-1 and NGAL levels.

Results The median levels of urine uNGAL (p < 0.05), uNGAL/creatinine (cr.) ratio (p < 0.0001) and uKIM-1/creatinine ratio (p < 0.0001) were significantly higher in ALL survivors in comparison with healthy controls. Female patients had significantly higher levels of NGAL and NGAL/cr. than males (mean 8.42 ± 7.1 vs. 4.59 ± 4.5 ng/mL and 86.57 ± 77 vs. 37.7 ± 37 ng/mg, respectively; p < 0.01). Of all the study participants, 11 (13%) presented eGFR below 90 mL/min/1.73 m². The NGAL/cr. ratio seemed to be the best predictor of decreased eGFR (AUC = 0.65). The cumulative dose of methotrexate and cyclophosphamide did not predict the values of the urine NGAL, NGAL/cr., KIM-1/cr. and eGFR.

Five years after the end of treatment, the patients had higher levels of uKIM-1 (1.02 ± 0.8 vs. 0.62 ± 0.6 ng/mL, p < 0.01), uNGAL (7.9 ± 6.7 vs. 4.6 ± 5 ng/mL, p < 0.01) and lower eGFR (114 ± 29 vs. 134 ± 35 mL/min/1.73 m², p < 0.01) in comparison with ALL survivors with the observation period of less than 5 years.

Conclusion We demonstrated that ALL survivors have higher levels of urine NGAL, NGAL/cr. and uKIM-1/cr. ratio as compared to the control group. Further long-term follow-up studies are necessary to assess the significance of the NGAL and KIM-1 and their relationship to kidney damage after anticancer treatment in childhood.

Keywords Urine KIM-1 · Urine NGAL · Acute lymphoblastic leukemia · Chronic kidney diseases · Childhood cancer survivors · CCS

Introduction

In the last years, progress in the diagnosis and treatment of childhood cancer has resulted in up to 80% of patients achieving remission or permanent healing. Through long-term observations of patient cohorts, we have learned a lot about the early and long-term effects of anticancer treatment. Nowadays, the main goal, apart from achieving the best possible treatment outcome, is to maintain good health after therapy termination. Nephrotoxicity (glomerulopathy, tubulopathy) is a potential late effect of cancer treatment in childhood. It is well known that
some cytostatic agents such as cisplatin, ifosfamide and abdominal radiotherapy or total body irradiation (TBI) may induce acute kidney injury (AKI) and/or long-term deterioration of kidney function [1–5].

Acute lymphoblastic leukemia (ALL) is the most common neoplastic disease in childhood and shows an overall survival between 80 and 98% depending on the risk group [6]. The most nephrotoxic cytostatics (cisplatin, ifosfamide) are not included in leukemia treatment protocols. However, other anticancer agents such as methotrexate or cyclophosphamide that are widely used may impair kidney function. Additionally, some antibiotics (e.g., aminoglycosides, vancomycin, amphotericin), proton pump inhibitors, analgesics (e.g., paracetamol, ibuprofen) as well as contrast media used in computed tomography may induce kidney injury. In our previous study assessing the prevalence of late effects of anticancer treatment in Poland, 88.25% of survivors had one or more symptoms/complaints indicating dysfunction of at least one organ. Of all patients treated for ALL in that study, 24.6% presented with symptoms suggestive for urinary tract dysfunction (information was collected on the basis of: medical history, questionnaire, physical examination and laboratory results). No severe or life-threatening health conditions (3rd and 4th grades according to CTCAE) were observed, yet there were subclinical or first-degree symptoms [7].

Serum creatinine level and estimated glomerular filtration rate (eGFR) are the simplest and most commonly used methods for assessing kidney function. On the other hand, several limitations of this method exist due to the influence of, among others, muscle mass, age, sex and hydration status. Moreover, the deterioration of kidney function may be very long unnoticed in clinical and laboratory tests, as it is often the case in chronic kidney disease (CKD). For this reason, new biomarkers are constantly being sought to reflect in particular the initial stage of kidney damage. In recent years, new biomarkers have been used to detect early onset of acute kidney injury, such as neutrophil gelatinase-associated lipocalin (NGAL), a member of the lipocalin family, and kidney injury molecule-1 (KIM-1), type 1 transmembrane glycoprotein.

NGAL is detected in various types of human tissues including kidneys (monomeric form), gastrointestinal and respiratory tract. Furthermore, its neutrophil dimeric form also participates in the immunological response. In healthy subjects, it is present in serum and urine at very low levels. Due to the low molecular weight and low degradation, NGAL is excreted into the urine (uNGAL) and its concentration increases immediately in the first hours after AKI. In kidneys, NGAL is excreted from the loop of Henle epithelial cells, the proximal and distal tube, and its level increases in line with the degree of renal tubular damage (toxic, ischemic) [8].

Kidney injury molecule-1 (KIM-1) is not detectable in health conditions. However, in the case of acute kidney damage, its excretion in proximal tubule cells in response to AKI is significantly increased [9–13]. Essentially, KIM-1 is useful as a marker of proximal tubular injury, whereas NGAL is a marker of proximal and distal tubule damage in response to various types of injury (i.e., ischemic, toxic, inflammation).

The available reports about the applicability of NGAL and KIM-1 as prognostic factors for early stages of chronic kidney damage are conflicting [12, 14–17]. In the literature, NGAL and KIM-1 levels have been studied as biomarkers detecting kidney injury during anticancer treatment with cytostatics such as ifosfamide and/or cisplatin. However, there are no studies assessing the usefulness of these markers in detecting early stages of CKD in long-term childhood cancer survivors [18–20].

The aim of the present study was to test the hypothesis that urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are increased in survivors of childhood acute lymphoblastic leukemia many years after treatment.

Materials and methods

Study population

A total of 86 out of 106 patients treated between 1996 and 2007 in childhood for acute lymphoblastic leukemia were enrolled in the study. Eligible patients included any individual who visited the outpatient clinic for a follow-up after treatment completion. All of them were in complete first continuous remission. Exclusion criteria were: relapse, hematopoietic stem cell transplantation, solitary functional kidney, any congenital anomalies of kidney or urinary tract, and current infection. All the children were treated in accordance with the international Berlin–Frankfurt–Münster (BFM) protocols approved by the Polish Pediatric Leukemia and Lymphoma Group. Written informed consent was obtained from the participants or their parents/guardians. The study was approved by Ethical Committee of the Medical University of Bialystok in line with the Declaration of Helsinki (permission number: R-I-002/62/2018).

For all subjects, clinical history including demographic information, coexisting diseases, previous anticancer treatment, cumulative dosage of nephrotoxic drugs (cyclophosphamide, methotrexate) and radiotherapy was obtained from medical records. The total cumulative glucocorticoids dosage was calculated with prednisone equivalent [21]. Every patient underwent full physical examination. Weight was measured on an electronic scale (Seca, Germany) and height was taken using a Martin anthropometer. Body mass index (BMI) was calculated according to the formula: weight [kg]/
height $^2$ [m$^2$]. Blood pressure was measured using a standard-
ized sphygmomanometer (performed three times at 1–2-min
intervals); before the measurement, the participant rested
peacefully for 5 min. The average values of the second and
third measurements of systolic blood pressure (SBP) and
diastolic blood pressure (DBP) were used for subsequent
analyses. Hypertension (HT) was defined as a mean SBP
and/or DBP level $\geq$ 95th percentile adjusted for age, sex and
height [22].

The control group consisted of 53 healthy peers (29
female) with a pair of normal kidneys, who were offspring
of the Pediatric and Nephrology Department’s employees
and healthy school pupils recruited form the OLAF study
[23]. All the study participants had a normal ultrasound
examination of the kidney and urinary tract performed by
an experienced pediatric radiologist.

**Biochemical analysis**

All laboratory tests were performed after 12-h night fasting.
The biochemical analyses included an assessment of serum
creatinine level (enzymatic method) and the estimated glo-
merular filtration rate (mL/min/1.73 m$^2$) calculated using
the updated Schwartz formula: eGFR = 0.143 $\times$ (height in
cm / serum cr. in mg/dL). Clean clean urine samples were
collected in the morning and stored at $-$80°C. Commer-
cial immunoassays (R&D SYSTEMS a bio-techne brand,
Quantikine® ELISA, Minneapolis, USA) were used to
measure urine KIM-1 and NGAL levels and the values were
expressed in nanograms per milliliter. All specimens were
diluted to obtain the concentration for the optimal measure-
ment in accordance with the instructions for the ELISA kit.
Due to the fact that different urine dilutions may affect the
concentration of the tested biomarkers, we calculated both
urine KIM-1 and NGAL levels per milligram urine creati-
nine (cr.) (KIM-1/cr. and NGAL/cr. ratios, respectively).
Urine albumin concentration was determined by Lowry’s
method and the results were expressed in μg/mL. Children
with a urinary albumin/creatinine ratio between 30 and
300 μg/mg were considered to have albuminuria. All the
measurements were done after the end of anticancer treat-
ment during follow-up visit (at least 6 months after comple-
tion of treatment).

**Statistical analysis**

Statistical analysis was performed using STATA 12.1 ver-
sion (StatCorp, College Station, Texas, USA). Data were
expressed as median (Me) and quartiles (Q) or mean and
standard deviation (SD) when appropriate. All continuous
variables were tested for normal distribution using Shapiro–Wilk or Kolmogorov–Smirnov tests. In the univariate
analysis, Fisher exact test and Chi square ($\chi^2$) test were
used. Continuous variables were compared with the Wil-
coxon rank-sum or $t$ Student test depending on the normal
distribution. Univariate and multivariate logistic regression
models with urine KIM-1/cr. and NGAL/cr. as independ-
ent variables were created. The correlations between vari-
ables were calculated by Spearman or Pearson correlation
coefficients. The diagnostic value of the biomarkers and the
optimum cut-off values were determined based on receiver
operating characteristic (ROC) analysis, known as the area
under the curve (AUC). Based on a rough classifying sys-
tem, AUC was interpreted as follows: 90–100 (excellent),
80–90 (good), 70–80 (fair), 60–70 (poor), < 60 (fail). A $p$
value below < 0.05 was considered significant.

**Results**

The clinical characteristics of study and control group
are shown in Table 1. The median age at the time of diag-
nosis was 4.24 years (range: 0.5–17.9 years), while the
median time from treatment cessation to follow-up was
6.55 ± 5.1 years (range 0.5–22.8 years). Age and sex did not
differ between the study and reference group.

Compared to the control group, the ALL patients had
higher values of creatinine level (0.57 vs. 0.49, $p < 0.05$),
although the difference was not shown in the eGFR value
(122 ± 33 vs. 124 ± 37 mL/min/1.73 m$^2$, $p > 0.05$). The sum-
mary of the biochemical parameters of all studied patients
is presented in Table 2. All subjects had normal eGFR prior
to treatment and no differences were found compared to the
control group.

Both ratios, KIM-1/cr. and NGAL/cr., were significantly
higher in ALL survivors in comparison with healthy con-
trols, $p < 0.0001$ (Figs. 1 and 2). Moreover, NGAL levels
(nmol/L) were found to be higher in the study group (mean
6.46 ± 6.2 vs. 0.005 ± 0.004, $p < 0.0001$), but not KIM-1
(mean 6.87 ± 6.1 vs. 0.81 ± 0.4 nmol/L, $p = 0.335$). In CCS,
we found a positive correlation between KIM-1 and NGAL
concentration ($r = 0.21$, $p < 0.05$) (Fig. 3). Female patients
had significantly higher level of NGAL and NGAL/cr. ratio
than males (mean 8.42 ± 7.1 vs. 4.59 ± 4.5 and 86.57 ± 77
vs. 37.7 ± 37, respectively; $p < 0.01$) but no differences in
concentration of KIM-1 and KIM-1/cr. ratio were found.

Among all the study participants, there were 11 (13%)
who presented eGFR below 90 but over 60 mL/min/1.73 m$^2$
(Table 3). Higher values of NGAL/cr. ratio were found in the
subgroup of patients with decreased eGFR in comparison
with those who had normal eGFR (74 ± 34 vs. 61 ± 68 ng/
mg, $p < 0.05$). There were no differences in KIM-1 or
KIM-1/cr. levels between groups depending on eGFR. Fur-
thermore, no link was found between albuminuria and all
the above parameters.
ROC analyses were conducted to assess the diagnostic profile of KIM-1 and NGAL in identifying patients with an impaired renal function (eGFR < 90 mL/min/1.73 m²). We found that NGAL/cr. showed poor diagnostic factor profile, describing an area under curve (AUC) of 0.65 (95% CI: 0.49–0.79) with the best cut-off value of 19.14 ng/mg (sensitivity 100%, specificity 32.3%), whereas KIM-1/cr. turned out to be a fail predictor of reduced eGFR (AUC 0.44; 95% CI: 0.25–0.62).

Given the fact that children in the first years of life might be more vulnerable to drug-induced nephrotoxicity, the study group was divided according to the time of diagnosis (0.5–3 years vs. 3 years and above); however, no differences in the concentration of the analyzed biomarkers were found. Interestingly, forty-eight subjects over 5 years after the end of treatment had higher levels KIM-1 (1.02 ± 0.8 vs. 0.62 ± 0.6 ng/mL, \( p < 0.01 \)), NGAL (7.9 ± 6.7 vs. 4.6 ± 5, \( p < 0.01 \)) and lower eGFR (114 ± 29 vs. 134 ± 35 mL/}

| Table 1 | Clinical characteristics of the survivors of acute lymphoblastic leukemia (ALL) and control group |
| --- | --- | --- | --- |
| **ALL** | **Control group** |
| Number (%)\(^a\) | Median (IQR)\(^c\) | Number (%)\(^a\) | Median (IQR)\(^c\) |
| Patients | 86 (100) | 53 (100) |
| Male | 44 (51.1) | 24 (45.3) |
| Female | 42 (48.9) | 29 (54.7) |
| Age at diagnosis (years) | 86 (100) | 4.24 (2.86–6.96) | 86 (100) | 12 (6.76–16.00) |
| Age at study (years) | 86 (100) | 6.55 (1.96–9.93) |
| Follow-up after treatment (years) | 86 (100) | 53 (100) | 11.5 (7.45–15.24) |
| Chemotherapy\(^e\) | 86 (100) | |
| Methotrexate (cumulative dose in mg/m²) | 8000 (8000–8000) | 10,050 ± 5494\(^b\) |
| Cyclophosphamide (cumulative dose in mg/m²) | 3000 (3000–3000) | 3620 ± 2349\(^b\) |
| Glucocorticoids (cumulative dose in mg/m²)\(^d\) | 3087 (3087–3087) | 3314 ± 944.3\(^b\) |
| Radiotherapy | 9 (10.5) | 12 (12–12) | 12.5 ± 1.73\(^b\) |
| No | 77 (89.5) |

**ALL acute lymphoblastic leukemia**

\(^a\)Percent of the total
\(^b\)Mean and standard deviation (SD)
\(^c\)Median and interquartile range (IQR)
\(^d\)Calculated as prednisone equivalents
\(^e\)Most patients received the same dosage of anticancer agents according to the treatment protocol; therefore, the first and third quartiles did not differ from the median

| Table 2 | Summary of the biochemical parameters of all studied patients |
| --- | --- | --- | --- |
| **Total** | **ALL survivors** | 86 | **Control group** | 53 | **\( p \)** |
| Serum creatinine (mg/dL) | 0.57 (0.42–0.74) | 0.49 (0.4–0.63) | <0.05 |
| eGFR (mL/min/1.73 m²) | 115.8 (100–140.9) | 118.1 (102.9–135.6) | 0.875 |
| KIM (ng/mL) | 0.59 (0.19–1.34) | 0.81 (0.41–1.04) | 0.335 |
| KIM/cr. (ng/mg cr.) | 5.71 (3.06–8.64) | 0.92 (0.44–1.48) | <0.0001 |
| NGAL (ng/mL) | 4.85 (1.92–7.96) | 0.004 (0.001–0.005) | <0.05 |
| NGAL/cr. (ng/mg cr.) | 42.11 (13.85–76.34) | 0.004 (0.001–0.007) | <0.0001 |

**ALL acute lymphoblastic leukemia, eGFR estimated glomerular filtration rate, KIM-1 urinary kidney injury molecule-1, NGAL urinary neutrophil gelatinase-associated lipocalin, cr. creatinine**

Data are given as the median with interquartile range
min/1.73 m², \( p < 0.01 \) as compared to those whose follow-up time did not exceed 5 years at the study time (38 patients) (Fig. 4). Further analysis checked the relationships between risk groups (standard/intermediate and high), but no relationships were identified. We also found that the NGAL and NGAL/cr. ratio were positively correlated with BMI (\( r = 0.4, p < 0.01 \)). No correlation was observed between high systolic and/or diastolic blood pressure and the investigated biomarkers.

Univariate analyses of KIM-1/cr. and NGAL/cr. with clinical parameters related to the applied treatment (cumulative doses of methotrexate and cyclophosphamide) did not show any significant differences. Summary of the analyzed parameters depending on the dosage of chemotherapeutic agents is presented in Table 4. Cut-off points were determined based on available studies and/or median and quartile ranges. Multivariate models assessing the relationship between KIM/cr. and NGAL/cr., potentially nephrotoxic factors such as cumulative dose of methotrexate, cyclophosphamide or abdominal radiotherapy, and reduced eGFR showed no differences.

Discussion

The influence of anticancer treatment, especially radiotherapy and nephrotoxic agents such as ifosfamide and cisplatin, on kidney function is well known in patients with solid tumors treated in childhood [2, 3, 5]. This study is a consequence of our earlier reports suggesting that kidney abnormalities may occur in up to 25% of patients after leukemia treatment, in which none of the enrolled individuals developed serious signs of renal failure. In the current study we were trying to establish whether urinary KIM-1 and NGAL are elevated in survivors of childhood ALL patients compared to control group. Our previous research failed to show any changes in cystatin C level during and after the treatment for ALL; however, the sample size was small [24]. In the last years, new biomarkers indicating the development of AKI have been introduced. In adult patients, as well as in children treated for different cancers, elevated urine excretion of NGAL and KIM-1 was observed immediately or several days after the infusion of cisplatin or ifosfamide. Their concentrations increased with the severity of tubular injury [8, 18, 20]. Sterling et al. studied the changes in NGAL and II-18 levels in the group of children treated with cisplatin, carboplatin and/or ifosfamide, and in the group with or without the symptoms of AKI [25]. They found higher NGAL levels after ifosfamide infusion in both AKI and non-AKI patients, but a greater and faster increase in biomarker levels was observed in AKI patients. This finding suggests that NGAL may be a useful predictor for detecting subclinical AKI. Similar studies, but only during intensive treatment, were carried out on the impact of methotrexate infusions.
One of the first surveys was based on creatinine level during and immediately after MTX infusions. They indicated the detrimental effect of methotrexate on renal function by lowering creatinine clearance and increasing serum creatinine, especially in patients with delayed MTX elimination [26–28]. In a group of 20 children with newly diagnosed ALL, treated with MTX at a dose of 5 g/m², Ylinen et al. observed an elevated cystatin C concentration 36 h after the infusion, but no changes in NGAL level were noted [29].

On the contrary, Li et al. in a group of children treated with different doses of methotrexate: 2, 3 and 5 g/m² (according to the risk groups) found that patients who received doses higher than 3 g/m² more often presented AKI with a parallel increase in urinary NGAL excretion. The authors suggested higher usefulness of the combination of serum creatinine ratio and serum NGAL (24 h after MTX infusion) for detecting AKI induced by a high dose of MTX compared with the serum creatinine ratio [11].

The results of NGAL and KIM-1 examinations in chronic kidney disease as markers of its development are controversial [12, 17, 30]. Seibert et al. in adult patients diagnosed for CKD in the course of the following diseases: diabetes mellitus, hypertensive nephropathy, glomerulonephritis and autosomal dominant polycystic kidney disease, did not confirm the better usefulness of NGAL and KIM-1 as prognostic factors in comparison with standard albuminuria [12]. Other studies, on the contrary, suggest that these markers might be helpful as an indicator of AKI to CKD progression, corresponding to the histopathological changes in the kidneys or the degree of albuminuria in diabetic patients [14, 31].

In a study conducted in children with hyperuricemia, male, obese and hypertensive patients demonstrated higher urinary

### Table 3

| eGFR (mL/min/1.73m²) | Total | <90 mL/1.73 m² | <90 mL/1.73 m² | p |
|---------------------|-------|----------------|----------------|---|
| KIM-1 (ng/mL)       | 0.63 (0.20–1.40) | 0.24 (0.19–1.14) | 0.483 |
| KIM-1/cr. (ng/mg cr.) | 5.92 (3.00–9.10) | 4.76 (2.79–6.78) | 0.545 |
| NGAL (ng/mL)        | 4.43 (1.83–10.25) | 6.79 (3.28–7.80) | 0.496 |
| NGAL/cr. (ng/mg cr.) | 32.04 (13.48–71.88) | 69.93 (51.05–98.39) | <0.05 |

### Table 4

| Dose | Methotrexate | p | Cyclophosphamide | p |
|------|--------------|---|-----------------|---|
|      | <10 g/m²     | >10 g/m² | <4.5 g/m²       | >4.5 g/m² |
| Number of patients | 67 | 19 | 74 | 14 |
| Serum creatinine (mg/dL) | 0.57 ± 0.18 | 0.59 ± 0.26 | 0.957 | 0.56 ± 0.20 | 0.59 ± 0.21 | 0.676 |
| eGFR (mL/min/1.73m²) | 121 ± 33 | 125 ± 33 | 0.780 | 122 ± 34 | 121 ± 29 | 0.851 |
| Albuminuria (mg/L) | 28.9 ± 152 | 16.6 ± 35 | 0.883 | 27.2 ± 146 | 17.5 ± 43 | 0.325 |
| uKIM (ng/mL) | 0.88 ± 0.8 | 0.71 ± 0.5 | 0.729 | 0.87 ± 0.8 | 0.67 ± 0.5 | 0.543 |
| uKIM/cr. (ng/mg cr.) | 7.02 ± 6.6 | 6.37 ± 3.6 | 0.787 | 7.04 ± 6.4 | 5.94 ± 3.8 | 0.717 |
| uNGAL (ng/mL) | 6.59 ± 6.4 | 5.98 ± 5.3 | 0.975 | 6.18 ± 6.2 | 8.01 ± 6.1 | 0.188 |
| uNGAL/cr. (ng/mg) | 59.6 ± 61.4 | 68.7 ± 76.6 | 0.715 | 57.1 ± 59.2 | 87.0 ± 88.5 | 0.114 |
excretion of NGAL and KIM-1. The authors implied that this was probably a result of endothelial dysfunction, local inflammation in the kidneys or negative effect of hyperuricemia on renal tubules [32]. In turn, in children with diagnosed congenital hydronephrosis and normal kidney function, uKIM-1/cr. and uNGAL/cr. were elevated in comparison to healthy children, and after surgery the level of both markers gradually decreased [16]. Lobato et al. in children diagnosed with CKD, reported higher NGAL and KIM-1 levels in patients with progressive kidney insufficiency [33].

In cancer survivors treated during childhood for different neoplasms, a decline in kidney function was observed mainly after treatment with nephrotoxic cytostatics. Mulder et al. in a study carried out on a large cohort of CCS (1122 subjects), almost half of whom were patients treated in childhood for leukemia and lymphoma, found glomerular deterioration (GFR < 90 mL/min/1.73 m²) in 1.7% of patients after 15 years of diagnosis, and in 6.6% after 35 years [1]. They explained it as a consequence of physiological and pathological aging. They found no changes in GFR in survivors treated previously with high doses of MTX [1]. In another study by Mundi et al. in which the majority of participants were also patients after leukemia treatment, eGFR reduction, electrolyte disturbances, proteinuria, hematuria and/or hypertension after treatment with ifosfamide or nephrectomy were observed [34].

According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, CKD is defined by structural or functional abnormalities of the kidney for ≥ 3 months, with or without decreased eGFR or eGFR < 60 mL/min/1.73 m² for ≥ 3 months, with or without kidney damage. An estimated GFR test may not correctly identify early symptoms or subtle progression of worsening kidney function. The assessment of serum creatinine levels has some limitations, including the influence of body lean mass, diet, patient’s physical activity and the time lag between the deterioration of kidney function and an increase in serum creatinine levels. Furthermore, some authors suggested that due to the curvilinear relationship between sCr and eGFR, the serum creatinine levels were increased when more than 40% of renal parenchyma was damage which may lead to the lack of detection of early stages of chronic kidney failure [35].

There is a need to discover new biomarkers, preferably non-invasive (especially in children) to predict deteriorating kidney function and identify patients in the early stages of the disease.

In our study, lowered eGFR values (< 90 mL/min/1.73 m²) were found in 13% of ALL survivors. We retrospectively checked data about eGFR measurement at least 3 months before the study time. All subjects with eGFR < 90 mL/min/1.73 during the study had also decreased eGFR three months earlier, but not < 60 mL/min/1.73 m². None of participants met the criteria of CKD according to KDIGO guidelines. Considering the whole group of the patients studied, higher levels in urine NGAL (p < 0.05), NGAL/cr. ratio and KIM-1/cr. ratio were observed as compared to the control group (p < 0.0001). Higher values of NGAL/cr. (but not KIM-1/cr.) were found in the subgroup of patients with decreased eGFR in comparison with those who had normal eGFR; however, the sample size was small. ROC analyses revealed that among all analyzed parameters NGAL/cr. was the greatest predictor of decreased eGFR (< 90 mL/min/1.73 m²); however, the diagnostic profile was poor. It might be due to the low percentage of survivors with decreased eGFR and presumably quite young mean age at follow-up visits. We observed a correlation between NGAL and KIM-1 values but there was no correlation between the analyzed biomarkers and albuminuria. Lower eGFR and elevated tubular markers were found in ALL patients who survived more than 5 years after the end of treatment as compared to those whose follow-up time was less than 5 years. However, to determine whether the time after treatment affects the marker concentration, a longitudinal study should be performed on the same group of patients.

We did not observe the effect of age at diagnosis as well as the cumulative MTX dose. Higher levels of serum creatinine, KIM-1 and NGAL in urine and lower eGFR in the group with a longer follow-up (> 5 years) may predict worsening of kidney function many years after treatment. Elevated urine KIM-1 and NGAL levels indicate the possibility of subclinical tubular injury in those survivors who do not present “classical” chronic kidney disease as defined by KDIGO. These subtle changes in the eGFR, as well as in uNGAL and uKIM-1, may suggest the first subclinical sings of renal dysfunction and therefore may help identifying ALL survivors who are predisposed to progressive renal impairment. However, we realize that the time that has passed since the end of the therapy seems to be too short to draw final conclusions. Thus, further observational and longitudinal studies on the large cohort of ALL patients are required.

The trend towards higher NGAL level in women was observed in our study group and was confirmed by some authors in healthy children and adults [36]. Additionally, NGAL and NGAL/cr. levels correlated with BMI but no association was found with overweight and obese patients. This finding is in accordance with some results that elevated urinary excretion of NGAL may be associated with higher BMI [37–39].

In our opinion, this is the first study concerning the analysis of tubular injury biomarkers in acute lymphoblastic leukemia survivors. Previous studies on other markers provided divergent results. Grönroos et al. in a prospective, but small study (28 survivors), evaluated glomerular and tubular function. They found a gradual decrease in GFR during follow-up but no changes in tubular function, i.e., normal blood electrolyte levels and normal urine
α1- and β-2-microglobulin. Median eGFR value after the end of follow-up was 113.9 mL/min/1.73m², and only 11% of survivors had reduced GFR <90 mL/min/1.73m² [36]. Dekkers et al. did not observe glomerular and tubular dysfunction after MTX treatment in long-term survivors [41]. In one of the older studies, Bardi et al. noted normal cystatin C concentration and normal eGFR value, although elevated urinary NGAL was observed in 38% of leukemia/lymphoma survivors [42].

MTX is considered the main factor damaging kidney function; however, it has been suggested that this decline in renal function is reversible [5]. In our opinion, nephrotoxicity in childhood cancer survivors is multifactorial. Patients treated for leukemia are not only given MTX during antinecancer treatment, but also, at the same time, they are exposed to other nephrotoxic drugs, such as aminoglycosides, vancomycin, amphotericin or contrast media, which all may aggravate kidney damage.

According to Grönroos et al. patients treated with methotrexate in combination with nephrotoxic antibiotics presented some late effects of deterioration of glomerular filtration and significant incidence of albuminuria [40]. Additionally, cancer treatment promotes dysfunction of different organs, metabolic processes inducing premature aging of cells and various organs, telomere shortening, production of proinflammatory cytokines and generates free-radicals, which cause direct damage to DNA. These factors are present in childhood cancer survivors and may affect the normal kidney function [43, 44].

There are several limitations of this study. It was a single-center analysis, with a relatively small number of patients. We did not evaluate the levels of urine NGAL and KIM-1 before the start of treatment, during exposure to chemotherapy or at the end of therapy, when possible recovery from MTX infusions may occur. The effects of other nephrotoxic drugs used in supportive care were not studied as well. The strengths of our research include the homogenous group of acute lymphoblastic leukemia survivors, relatively long follow-up time and no ethnic diversity.

In conclusion, the results of this study demonstrated that ALL survivors have higher levels of urine NGAL, NGAL/cr. and uKIM-1/cr. ratio compared to the control group. Further longitudinal, prospective analyses of NGAL and KIM-1 levels in ALL survivors and their potential role as monitoring tools for kidney dysfunction remain to be performed.

Acknowledgments This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest The authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mulder RL, Knijnenburg SL, Geskus RB, van der Pal HJ, Koning CC, Bouts AH, Caron HN, Kremer LC (2013) Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer Epidemiol Biomarkers Prev 22:1736–1746
2. O’Sullivan D (2017) Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature. Ir J Med Sci 186:49–55
3. Skinner R (2018) Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatr Nephrol 33:215–225
4. Kooijmans ECM, Bökenkamp A, Tjahjadi NS, Tettero IM, van Duijmen-den BE, van der Pal HJ, Veening MA (2019) Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Data of Syst Rev. https://doi.org/10.1002/14651858.CD008944
5. Jones DP, Spunt SL, Green D, Springate JE (2008) Renal late effects in patients treated for cancer in childhood: a report from the children’s oncology group. Pediatr Blood Cancer 51:724–731
6. Cooper SL, Brown PA (2015) Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am 62:61–73
7. Krawczuk-Rybak M, Panasiuk A, Stachowiez-Stencel T, Zubowska M, Skalska-Sadowska J, Sega-Pondel D, Czajinska-Deptula A, Sławinska D, Badowska W, Kamieñska E, Pobudejka-Pieniążek A, Wieczorek M (2018) Health status of Polish children and adolescents after cancer treatment. Eur J Pediatr 177:437–447
8. Westhoff JH, Seibert FS, Waldherr S, Bauer F, Tönnbichler F, Fichtner A, Westhoff TH (2017) Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury. Eur J Pediatr 176:745–755
9. Griffin BR, Faubel S, Edelstein CL (2019) Biomarkers of Drug-Induced Kidney Toxicity. Ther Drug Monit 41:213–226
10. McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leader JS, Bonventre JV, Smyth RL, Pirmohamed M (2014) Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med 8:1189–1197
11. Li H, Xu Q, Wang Y, Chen K, Li J (2020) Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 85:95–103
12. Seibert FS, Sitz M, Passfeld I, Haesner M, Laschinski P, Buhl M, Bauer F, Babel N, Pagonas N, Westhoff TH (2008) Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease. Kidney Blood Press Res 43:1255–1262
13. McCaffrey J, Dhakal AD, Milford DV, Awebb NJ, Lennon R (2017) Recent developments in the detection and management of acute kidney injury. Arch Dis Child 102:91–96
14. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE (2011) Biomarkers in chronic kidney disease: a review. Kidney Int 80:806–821

15. Castillo-Rodríguez E, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A (2017) Kidney injury marker 1 and neotrophil gelatine-associated lipocalin in chronic kidney disease. Nephron 136:263–267

16. Wasilewska A, Taranta-Janusz K, Dębik W, Zoch-Zwierz W, Kuruczycya-Sanitucyz E (2011) KIM-1 and NGAL: new markers of obstructive nephropathy. Pediadri Nephrol 26:579–586

17. Hsu CY, Xie D, Walkar SS, Bonventre JV, Zhang X, Siffredi V, Mifflin TE, Coresh J, Diamantidis CJ, He J, Lora CM, Miller ER, Nelson RG, Ojo AO, Rahman M, Schelling IR, Wilson FP, Kimmel PL, Feldman HI, Vasan RS, Liu KD; CRIC Study Investigators: CKD Biomarkers Consortium (2017) Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 91:196–203

18. Maeda A, Ando H, Ura T, Muro K, Aoki M, Saito K, Kondo E, Takahashi S, Ito Y, Mizuno Y, Fujimura A (2017) Differences in urinary renal failure biomarkers in cancer patients initially treated with cisplatin. Anticancer Res 37:5235–5239

19. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, Kim YH, Mishima M, Ichimura T, Bonventre JV, Matsubara K (2015) Urinary kidney injury molecule-1 and monocyte chemoattractant protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 76:989–996

20. George B, Joy MS, Aleksunes LM (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med 243:272–282

21. Lim JS, Kim DH, Lee JA, Kim DH, Cho J, Cho WH, Lee SY, Jeon DG (2013) Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma. J Pediatr Hematol Oncol 35:54–60

22. Kulaga Z, Litwin M, Grajda A, Gurzewska B, Napieralska E, Kułaga Z, Litwin M, Grajda A, Gurzewska B, Grupa Badaczy OLAF (2010) Distribution of blood pressure in school-aged children and adolescents reference population. Stand Med 7:853–864

23. Kulaga Z, Litwin M, Grajda A, Kulaga K, Gurzewska B, Góźdź M, Pan H; OLAF Study Group (2012) Oscilometric blood pressure percentiles for Polish normal-weight school-aged children and adolescents. J Hypertens 30:1942–1954

24. Krawczuk-Rybak M, Kuzmicz M, Wysocka J (2005) Renal function during and after treatment for acute lymphoblastic leukemia. Pediatr Nephrol 20:782–785

25. Kułaga Z, Litwin M, Grajda A, Gurzewska B, Grupa Badaczy OLAF (2010) Distribution of blood pressure in school-aged children and adolescents reference population. Stand Med 7:853–864

26. Sterling M, Al-Ismaïli Z, McMahon KR, Riccioni M, Pizzi F, Mottes T, Lands LC, Abish S, Fleming AJ, Bennett MR, Palijan M, Devarajan P, Goldstein SL, O'Brien MM, Zappitelli M (2017) Reference values of osteosarcoma. J Pediatr Hematol Oncol 35:54–60

27. Yao M, Jahnukainen K, Saarinen-Pihkala UM, Jahnukainen T (2014) Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 61:2199–2202

28. Guo L, Zhao Y, Yong Z, Zhao W (2018) Evaluation value of neutrophil gelatine-associated lipocalin for the renal dysfunction of patients with chronic kidney disease: a meta-analysis. Aging Med (Milton) 1:185–196

29. Małyszko J, Bachorzewska-Gajewska H, Sitniewska E, Małyszko S, Poniatowski B, Dobrzycki S (2009) Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in nondiabetic patients with stage 2–4 chronic kidney disease. Ren Fail 30:625–628

30. Tomczak J, Wasilewska A, Milewski R (2013) Urine NGAL and KIM-1 in children and adolescents with hyperuricemia. Pediatr Nephrol 28:1863–1869

31. Lobato GR, Lobato MR, Thomé FS, Veronese FV (2017) Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-glucosaminidase to predict chronic kidney disease progression and adverse outcomes. Braz J Med Biol Res. https://doi.org/10.1590/1414-431X20176106

32. Mudi A, Levy CS, Geel JA, Poole JE (2016) Paediatric cancer survivors demonstrate a high rate of subclinical renal dysfunction. Pediatr Blood Cancer 63:2026–2032

33. Rysz J, Gluba-Brzózka A, Franczyk B, Jablonowski Z, Ciałkowska-Rysz A (2017) Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci 18:1702. https://doi.org/10.3390/ijms18081702

34. Bennett MR, Nebus E, Haffner C, Mu Q, Devarajan P (2015) Pediatric reference ranges for acute kidney injury biomarkers. Pediatr Nephrol 30:677–685

35. Gul A, Yılmaz R, Ozmen Z, Gumuser R, Demir O, Unsal V (2020) Valoración de la función renal en niños con sobrepeso y obesidad con las moléculas NGAL y KIM-1. Nutr Hosp. https://doi.org/10.20960/nh.02651 (Epub ahead of print)

36. Bostan Gayret Ö, Taşdemir M, Erol M, Tekin Naceroğlu H, Zengi O, Yiğit Ö (2018) Are there any new reliable markers to detect renal injury in obese children? Ren Fail 40:416–422

37. Goknar N, Oktiem F, Ozgen IT, Torun E, Çağkıncı M, Demir AD, Cesur Y (2015) Determination of early urinary renal injury markers in obese children. Pediatr Nephrol 30:139–144

38. Grönnroos MH, Jahnukainen T, Möttönen M, Perkkii M, Irija K, Salmi TT (2008) Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer 51:535–539

39. Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, van den Heuvel-Eibrink MM (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 8:922–929

40. Bardi EMD, Olah AV, Bartyik K, Endreyfi E, Jeni C, Kappelmayer J, Kiss C (2004) Late effects on renal glomerular and tubular function in childhood cancer survivors. Pediatr Blood Cancer 43:668–673

41. Krawczuk-Rybak M, Latoch E (2019) Risk factors for premature aging in childhood cancer survivors. Dev Period Med 23:97–103

42. Ariffin H, Azanan MS, Abd Ghafar SS, Oh L, Lau KH, Thiru navakarasu T, Sedan A, Ibrahim K, Chan A, Chin TF, Liew FF, Jeyamogan S, Rosli ES, Baharudin R, Yap TY, Skinner R, Lum SH, Hainaut P (2017) Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. Cancer 123:4207–4214

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.